



The Maryland State Medical Society  
1211 Cathedral Street  
Baltimore, MD 21201-5516  
410.539.0872  
Fax: 410.547.0915  
1.800.492.1056  
www.medchi.org

House Health Committee

March 10, 2026

House Bill 1477 – *Public Health – Ibogaine Clinical Research Grant Program – Establishment (Veterans Mental Health Innovations Act)*

**POSITION: OPPOSE**

The Maryland State Medical Society (MedChi), the largest physician organization in Maryland, respectfully **opposes** House Bill 1477.

House Bill 1477 establishes an Ibogaine Clinical Research Grant Program within the Maryland Department of Health to fund U.S. Food and Drug Administration (FDA) clinical trials studying ibogaine for opioid use disorder and certain neurological conditions, using Opioid Restitution Fund dollars. The bill authorizes time-limited grants to eligible Maryland research institutions and requires reporting to the General Assembly on study progress and outcomes.

Maryland’s physicians remain committed to addressing opioid use disorder, veteran mental health challenges, and the ongoing overdose crisis. We strongly support rigorous scientific research into safe and effective treatments. However, House Bill 1477 would allocate Opioid Restitution Fund dollars to support clinical drug development trials for ibogaine, a substance with a limited evidence base and a documented history of significant safety concerns, before sufficient foundational data have established an acceptable risk profile.

Ibogaine is not approved by the FDA for any medical use. Published research has identified serious safety concerns associated with its use, particularly effects on the heart. Medical case reports and toxicology reviews have also documented deaths occurring after ibogaine use, often involving heart-related complications or interactions with other substances. These risks are especially concerning for individuals with opioid use disorder, who may have underlying health conditions, ongoing substance use, or be taking medications that can also affect heart rhythm.

At a time when Maryland continues to face record numbers of overdose deaths, workforce shortages, and limited access to established overdose treatments, MedChi believes that opioid abatement funds should be directed toward scalable interventions with demonstrated safety and effectiveness.

Allocating \$500,000 annually in Opioid Restitution Fund dollars to support early-phase clinical research may divert resources from community-based prevention, treatment access, recovery services, and harm reduction efforts that have established efficacy and immediate impact. Until stronger evidence is available, dedicating state opioid settlement funds to this bill’s purpose is premature.

For these reasons, MedChi requests an unfavorable report on House Bill 1477.

**For more information call:**

Christine K. Krone  
J. Steven Wise  
Danna L. Kauffman  
Andrew G. Vetter  
410-244-7000